title: Low expression of NQO1 predicts pathological complete response to neoadjuvant chemotherapy in breast cancer patients treated with TAC regimen.
abstract: The aim of this study was to evaluate preoperative           tumour expression of NAD(P)H:quinone           oxidoreductase 1 (NQO1) along with other biological           markers as potential predictors of pathological complete           response (pCR) to neoadjuvant docetaxel, doxorubicin,           and cyclophosphamide-containing (TAC)           chemotherapy in patients with primary breast cancer.           Sixty-one patients who received neoadjuvant           chemotherapy (NCT) with TAC regimen were enrolled           in this prospective study. The pre- and post-           NCT expression of oestrogen receptor (ER), progesterone           receptor (PR), epidermal growth factor           receptor 1 and 2 (EGFR and HER2), NQO1, Ki-67           proliferation index, multidrug resistance protein 1           (MDR1), p53 and BCL2 were evaluated by immunohistochemistry.           The pCR was reached in 14 patients           (23 % of the study group). Multivariate analysis demonstrated that patients with ER-, PR-, NQO1-           negative, and Ki-67-positive tumours had a significantly           higher chance to achieve pCR. Within the biological           subtypes, the highest pCR rate (50 %) was           seen in triple-negative (i.e. ER-, PR-, HER2-) tumours.           Post-operative evaluation showed that in           comparison to pre-operative tissue samples, NQO1           expression was significantly increased, while Ki-67           and HER2 decreased, in the residual tissue after           NCT. In conclusion, the present data suggests that           NQO1 expression may be a novel diagnostic biomarker           for the prediction of positive response to           NCT in patients with breast cancer.
authors.affiliation: Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Teaching Hospital in Hradec Králové, Czech Republic. grimj@lfhk.cuni.cz
authors.forename: J
authors.initials: J
authors.lastname: Grim
authors.forename: P
authors.initials: P
authors.lastname: Jandík
authors.forename: I
authors.initials: I
authors.lastname: Slánská
authors.forename: E
authors.initials: E
authors.lastname: Doležalová-Brčáková
authors.forename: L
authors.initials: L
authors.lastname: Fuksa
authors.forename: A
authors.initials: A
authors.lastname: Ryška
authors.forename: J
authors.initials: J
authors.lastname: Knížek
authors.forename: J
authors.initials: J
authors.lastname: Petera
authors.forename: S
authors.initials: S
authors.lastname: Mičuda
authors.forename: H
authors.initials: H
authors.lastname: Hornychová
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism*; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D016660:NAD(P)H Dehydrogenase (Quinone); C447479:NQO1 protein, human